109-38: Sarepta Numerology Headed Toward May 26 Deadline On Eteplirsen
This article was originally published in RPM Report
It sounds like a lopsided high-school basketball score; but 109-38 is the ratio of members of Congress urging approval to Duchenne Muscular Dystrophy patients who have completed efficacy trials with eteplirsen. It is the kind of score that creates a tough challenge for an FDA decision.
You may also be interested in...
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.
AstraZeneca devoted a surprisingly large piece of its testimony at the recent House vaccine hearing to its therapeutic work. The company appears to be anticipating another shift in public attention back to the mAB cocktail as a way to treat and prevent COVID-19.
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.